NEW YORK (GenomeWeb News) – Global Genomics Group and Metabolon today announced a collaboration aimed at discovering novel biomarkers and drug targets for cardiovascular diseases.

As part of the deal, Metabolon will use its TrueVision metabolomics offering to analyze biochemicals for a study called Genetic Loci and Burden of Atherosclerotic Lesions, or GLOBAL. The study combines genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and lipoprotein proteomics with coronary computed tomographic angiography.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.